drugset / Trial / NCT02170805
Bioavailability of BIBR 1048 MS Single Doses With or Without Pantoprazole in Healthy Subjects
RandomizedCrossoverOpen-labelTreatment
Summary
The pharmacokinetics of 50 mg BIBR 1048 administered as two newly developed capsule formulation using melt extrusion technology was assessed in two separate, single dose, 3-way crossover, open design, randomised studies. The 3-way crossover treatments included administration of the tartaric acid solution of 50 mg BIBR 1048, the capsule formulation A or B and administration of the capsules with coadministration of pantoprazole.
Timeline
- Start
- 2001-04
- Primary completion
- 2001-06
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dabigatran etexilate | Unknown | 50 mg | Oral |
| Subject | Pantoprazole | Other / unclassified | 40 mg | — |
Indications
No indication recorded.